NASDAQ:PTLA - Portola Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $30.15 +0.20 (+0.67 %) (As of 02/21/2019 04:00 PM ET)Previous Close$29.95Today's Range$29.0574 - $30.3552-Week Range$14.81 - $46.28Volume1.38 million shsAverage Volume1.71 million shsMarket Capitalization$2.00 billionP/E Ratio-6.27Dividend YieldN/ABeta2.24 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Portola Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics that could advance the fields of thrombosis and other hematologic diseases. The company's two FDA-approved medicines are Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo), an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor candidate for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Dermavant Sciences GmbH; and Ora, Inc. The company was founded in 2003 and is headquartered in South San Francisco, California. Receive PTLA News and Ratings via Email Sign-up to receive the latest news and ratings for PTLA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTLA Previous Symbol CUSIPN/A CIK1269021 Webwww.portola.com Phone650-246-7000Debt Debt-to-Equity Ratio1.21 Current Ratio6.61 Quick Ratio6.51Price-To-Earnings Trailing P/E Ratio-6.27 Forward P/E Ratio-6.03 P/E GrowthN/A Sales & Book Value Annual Sales$22.55 million Price / Sales88.82 Cash FlowN/A Price / Cash FlowN/A Book Value$5.36 per share Price / Book5.63Profitability EPS (Most Recent Fiscal Year)($4.81) Net Income$-286,090,000.00 Net Margins-1,020.52% Return on Equity-135.08% Return on Assets-69.69%Miscellaneous Employees252 Outstanding Shares66,434,000Market Cap$2.00 billion Next Earnings Date3/1/2019 (Confirmed) OptionableOptionable Portola Pharmaceuticals (NASDAQ:PTLA) Frequently Asked Questions What is Portola Pharmaceuticals' stock symbol? Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA." How were Portola Pharmaceuticals' earnings last quarter? Portola Pharmaceuticals Inc (NASDAQ:PTLA) released its quarterly earnings data on Thursday, August, 9th. The biopharmaceutical company reported ($1.61) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.49) by $0.12. The biopharmaceutical company had revenue of $4.01 million for the quarter, compared to the consensus estimate of $6.35 million. Portola Pharmaceuticals had a negative net margin of 1,020.52% and a negative return on equity of 135.08%. The business's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.22) earnings per share. View Portola Pharmaceuticals' Earnings History. When is Portola Pharmaceuticals' next earnings date? Portola Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, March 1st 2019. View Earnings Estimates for Portola Pharmaceuticals. How can I listen to Portola Pharmaceuticals' earnings call? Portola Pharmaceuticals will be holding an earnings conference call on Friday, March 1st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8444526828. What price target have analysts set for PTLA? 6 analysts have issued 1-year price targets for Portola Pharmaceuticals' stock. Their forecasts range from $30.00 to $50.00. On average, they anticipate Portola Pharmaceuticals' share price to reach $35.50 in the next twelve months. This suggests a possible upside of 17.7% from the stock's current price. View Analyst Price Targets for Portola Pharmaceuticals. What is the consensus analysts' recommendation for Portola Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Portola Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Portola Pharmaceuticals. What are Wall Street analysts saying about Portola Pharmaceuticals stock? Here are some recent quotes from research analysts about Portola Pharmaceuticals stock: 1. According to Zacks Investment Research, "Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. " (2/21/2019) 2. Cowen Inc analysts commented, "Rhythm reported 2Q18 financial results yesterday and we spoke w/ mgmt for an update. As a reminder, the company completed enrollment of both setmelanotide Phase 3 trials in POMC and LepR Deficiency patients in Jun 2018. Mgmt reiterated guidance for results from these trials in 3Q19. We expect positive outcomes based on Phase 2 data. Encouraging long-term Phase 2 data in Bardet-Biedl (BBS) and initial Phase 2 data in Alstrom, POMC Heterozygous, and POMC Epigenetic were announced earlier this year and mgmt reiterated plans to start a single Phase 3 trial w/ both Bardet-Biedl and Alstrom patients in 2H18. Demonstration of consistent impact on appetite and weight across several genetic obesity diseases in 2Q18 has increased our conviction. BUY." (8/9/2018) Has Portola Pharmaceuticals been receiving favorable news coverage? Headlines about PTLA stock have been trending somewhat positive on Thursday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Portola Pharmaceuticals earned a media sentiment score of 0.6 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. Are investors shorting Portola Pharmaceuticals? Portola Pharmaceuticals saw a increase in short interest in January. As of January 15th, there was short interest totalling 18,815,496 shares, an increase of 17.9% from the December 31st total of 15,962,112 shares. Based on an average trading volume of 2,445,782 shares, the short-interest ratio is presently 7.7 days. Approximately 29.3% of the company's stock are short sold. View Portola Pharmaceuticals' Current Options Chain. Who are some of Portola Pharmaceuticals' key competitors? Some companies that are related to Portola Pharmaceuticals include Beigene (BGNE), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Loxo Oncology (LOXO), SAGE Therapeutics (SAGE), Perrigo (PRGO), Marina Biotech (MRNA), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), Alkermes (ALKS), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR) and Array Biopharma (ARRY). What other stocks do shareholders of Portola Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Portola Pharmaceuticals investors own include Novavax (NVAX), Exelixis (EXEL), NVIDIA (NVDA), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), Micron Technology (MU), Celgene (CELG), TG Therapeutics (TGTX) and Progenics Pharmaceuticals (PGNX). Who are Portola Pharmaceuticals' key executives? Portola Pharmaceuticals' management team includes the folowing people: Ms. Mardi C. Dier, Exec. VP, Chief Bus. Officer & CFO (Age 55)Dr. John T. Curnutte, Exec. VP and Head of R&D (Age 67)Mr. Tao Fu, Consultant (Age 47)Mr. J. Scott Garland MBA, Pres & CEO (Age 50)Cara Miller, VP of Investor Relations and Corp. Communications Who are Portola Pharmaceuticals' major shareholders? Portola Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.02%), Brandywine Global Investment Management LLC (1.26%), Sectoral Asset Management Inc (1.24%), Northern Trust Corp (1.21%), Geode Capital Management LLC (1.10%) and Tocqueville Asset Management L.P. (0.91%). Company insiders that own Portola Pharmaceuticals stock include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, Henry Ward Wolff, Jeffrey W Bird, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Institutional Ownership Trends for Portola Pharmaceuticals. Which major investors are selling Portola Pharmaceuticals stock? PTLA stock was sold by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, Bank of New York Mellon Corp, Asymmetry Capital Management L.P., Oppenheimer & Co. Inc., Hudson Bay Capital Management LP, Northern Trust Corp, Harvey Capital Management Inc. and Raymond James & Associates. Company insiders that have sold Portola Pharmaceuticals company stock in the last year include Charles J Homcy, Tao Fu and William Lis. View Insider Buying and Selling for Portola Pharmaceuticals. Which major investors are buying Portola Pharmaceuticals stock? PTLA stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Tamarack Advisers LP, Elk Creek Partners LLC, Foresite Capital Management IV LLC, Macquarie Group Ltd., Tocqueville Asset Management L.P., Empire Life Investments Inc. and grace capital. View Insider Buying and Selling for Portola Pharmaceuticals. How do I buy shares of Portola Pharmaceuticals? Shares of PTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Portola Pharmaceuticals' stock price today? One share of PTLA stock can currently be purchased for approximately $30.15. How big of a company is Portola Pharmaceuticals? Portola Pharmaceuticals has a market capitalization of $2.00 billion and generates $22.55 million in revenue each year. The biopharmaceutical company earns $-286,090,000.00 in net income (profit) each year or ($4.81) on an earnings per share basis. Portola Pharmaceuticals employs 252 workers across the globe. What is Portola Pharmaceuticals' official website? The official website for Portola Pharmaceuticals is http://www.portola.com. How can I contact Portola Pharmaceuticals? Portola Pharmaceuticals' mailing address is 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-246-7000 or via email at [email protected] MarketBeat Community Rating for Portola Pharmaceuticals (NASDAQ PTLA)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 421 (Vote Outperform)Underperform Votes: 265 (Vote Underperform)Total Votes: 686MarketBeat's community ratings are surveys of what our community members think about Portola Pharmaceuticals and other stocks. Vote "Outperform" if you believe PTLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTLA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2019 by MarketBeat.com StaffFeatured Article: How Does the Quiet Period Work?